A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors

Inclusion Criteria: 1. Agree to comply with the trial treatment plan and visit plan, voluntarily agree to sign the informed consent form; 2. 18-75 years old (including boundary value), no gender limit in the I/IIa trial phase；18-80 years old (including boundary value), no gender limit in the IIb trial phase； 3. Subject has adequate organ and bone marrow function，Conforming to laboratory test results: 4. The expected survival time is at least 12 weeks 5. ECOG score is 0-1 6. Males with fertility and females of childbearing age are willing to take effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug (including abstinence, intrauterine device, various hormonal contraception, correct use of contraception Sets，etc）; Women of childbearing age include pre-menopausal women and women within 2 years after menopause. Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered. Exclusion Criteria: 1. Receiving other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time; 2. Brain parenchymal metastases or meningeal metastases with clinical symptoms, which are not suitable for inclusion in the group by the investigator's judgment; 3. medical history of immunodeficiency including positive HIV antibody test; 4. Women who are pregnant or breastfeeding; 5. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in the study